Delving into the Latest Updates on Risperidone with Synapse

Overview

Basic Info

SummaryRisperidone, marketed under the trade name RISPERDAL®, is an atypical antipsychotic medication that was first approved by the US Food and Drug Administration (FDA) on December 29, 1993. Developed by Johnson & Johnson, risperidone is indicated for the treatment of schizophrenia, as well as acute manic or mixed episodes associated with bipolar I disorder, either as monotherapy or as an adjunctive therapy with lithium or valproate. It is also approved for the treatment of irritability associated with autism spectrum disorders. The drug's mechanism of action involves a combination of dopamine Type 2 (D2) and serotonin Type 2 (5HT2) receptor antagonism, which is believed to contribute to its therapeutic effects in treating schizophrenia. Risperidone is generally well-tolerated, but may cause side effects such as weight gain, drowsiness, and extrapyramidal symptoms.

Drug Type

Small molecule drug

Synonyms

Risperdal OD, Risperidone (JP17/USP/INN), Risperidone for Depot Suspension

+ [45]

Target

5-HT2A receptor x D2 receptor

Action

antagonists

Mechanism

5-HT2A receptor antagonists(Serotonin 2a (5-HT2a) receptor antagonists), D2 receptor antagonists(Dopamine D2 receptor antagonists)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

Bipolar I disorderAutistic DisorderAggression+ [7]

Inactive Indication

Acute schizophreniaAsperger SyndromeAttention Deficit and Disruptive Behavior Disorders+ [26]

Originator Organization

Johnson & Johnson

Active Organization

HLS Therapeutics, Inc.

Laboratorios Farmaceúticos Rovi SA

Janssen Pharmaceuticals, Inc.

+ [8]

Inactive Organization

Janssen Pharmaceutica NVJanssen-Cilag International NVJanssen-Cilag Ltd.

+ [12]

License Organization

Laboratorios Farmaceúticos Rovi SA

Teva Pharmaceutical Industries Ltd.

Orient Europharma Co. Ltd.

+ [5]

Drug Highest PhaseApproved

First Approval Date

United States (29 Dec 1993),

Schizophrenia

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC23H27FN4O2

InChIKeyRAPZEAPATHNIPO-UHFFFAOYSA-N

CAS Registry106266-06-2

The aim of this study is to evaluate the effect of a Spirulina syrup formulation on reducing anxiety in children with non-idiopathic autism. Participants are referred to a private clinic and assessed by a pediatric neurology subspecialist to confirm the diagnosis. Informed consent is obtained from the parents. Patients are randomly assigned to two groups. The intervention group receives standard treatment (Risperidone tablets) plus Spirulina syrup, while the control group receives Risperidone plus a placebo. Anxiety is measured using the parent version of the Spence Children's Anxiety Scale (SCAS), which includes 38 items rated on a 4-point Likert scale. The questionnaire is administered online via the Porsline platform, and links are sent nightly via social media starting before treatment and continuing daily for one week after treatment initiation, then regularly over a 3-month follow-up period. Data will be analyzed using SPSS version 16. The SCAS consists of six subscales: separation anxiety, social anxiety, phobia, generalized anxiety, panic, and obsessive-compulsive symptoms.

Start Date07 Jul 2025

Sponsor / Collaborator

Shahid Sadoughi University of Medical Sciences and Health Services

NCT06512220

/ RecruitingPhase 2IIT

Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)

Limit: 5000 characters. Psilocybin, the chemical component of "magic mushrooms", has been administered with psychotherapy in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects. In healthy volunteers, the psychedelic effects of psilocybin have been shown to be blocked by administration of certain medications such as risperidone.
The purpose of this study is to use an established SV2A radiotracer produced at our Centre to determine the feasibility of integrating PET imaging in to psilocybin trials. The preliminary imaging data will assess whether psilocybin's antidepressant effects are related to changes in synaptic density in adults with TRD, and whether any changes in synaptic density are associated with psilocybin's actions on the 5-HT2AR.

Start Date21 Apr 2025

Sponsor / Collaborator

Centre for Addiction & Mental Health

100 Clinical Results associated with Risperidone

Login to view more data

100 Translational Medicine associated with Risperidone

Login to view more data

100 Patents (Medical) associated with Risperidone

Login to view more data

12,927

Literatures (Medical) associated with Risperidone

01 Jan 2026·COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY C-TOXICOLOGY & PHARMACOLOGY

Neuroprotective effect of ferulic acid in valproic acid induced autism like behaviour in zebrafish via modulation of PI3K/AKT/mTOR pathway

Article

Author: Singh, Shamsher ; Chatterjee, Dhrita

Valproic acid (VPA), a widely used antiepileptic and mood stabilizing drug, is known to induce autism-like features when administered during neurodevelopment. Recent evidence suggests that VPA exposure during adulthood may also elicit autism spectrum disorder (ASD)-like features by altering key signalling pathways, such as phosphoinositide 3-kinase/AKT/mammalian target of rapamycin (PI3K-AKT-mTOR), and cause behavioural and neuromorphological deficits. The study explored the neuroprotective properties of ferulic acid (FA) in VPA-induced cognitive and behavioural impairments. Zebrafish were exposed to VPA at 500 μM for four consecutive days to induce ASD-like features. After 4 days of VPA exposure, they were treated with FA (50, 100, and 200 mg/kg) and risperidone (0.5 mg/kg) for 4 days. Behavioural (T-maze, Novel Tank Driving Test (NTDT), and social interaction), biochemical (oxidative markers), molecular changes (PI3K, mTOR by ELISA, and AKT by immunohistochemistry), and histopathological analyses were performed to confirm the neuroprotective properties of ferulic acid (FA). VPA (500 μM) exposure significantly deteriorated behavioural and molecular alteration levels (p < 0.001 vs. normal control group) in zebrafish. However, FA (100 and 200 mg/kg) significantly improved cognitive and behavioural alterations, as well as oxidative marker and neurotransmitter levels (p < 0.05 vs. VPA group) in zebrafish. Treatment also improved histopathological changes and AKT levels (p < 0.001 vs. the VPA group) in zebrafish. Our results demonstrated that the therapeutic effect of FA in VPA induced autism like symptoms in zebrafish was mediated by its antioxidant, anti-inflammatory, and anti-apoptotic properties through modulation of the PI3K-AKT-mTOR pathway, offering a promising therapeutic strategy for ASD-like symptoms.

01 Jan 2026·JOURNAL OF AFFECTIVE DISORDERS

Long-term treatment with lithium, valproate, and atypical antipsychotics on suicide risk in patients with bipolar disorder: A nationwide retrospective cohort study

Article

Author: Shin, Cheolmin ; Ko, Young-Hoon ; Yoon, Ho-Kyoung ; Tae, Bum Sik ; Choi, Hangseok ; Park, Sol A ; Jeong, Jong-Hyun ; Kwon, Do-Young ; Son, Serhim

BACKGROUND:

Patients with bipolar disorder exhibit higher suicide and mortality rates than the general population, owing to suicidal behaviors. This study examined the long-term effects of lithium, valproate, and atypical antipsychotics on suicide attempts and suicides among Korean patients with bipolar disorder.

METHODS:

This retrospective study used Korean healthcare claims data of 44,694 individuals (mean age 31.09 ± 9.81 years; 58.07 % female) with at least two principal diagnoses of bipolar disorder and at least two prescriptions for lithium, valproate, carbamazepine, or atypical antipsychotics (risperidone, quetiapine, olanzapine, aripiprazole, and ziprasidone) between 2002 and 2020. We examined the risk of suicide attempts and suicide during the period with each drug using Cox proportional regression.

RESULTS:

The risk of suicide incidents decreased by 39.2 % and 26.0 % during treatment with lithium alone (hazard ratio [HR] 0.608, 95 % confidence interval [CI] 0.434-0.852) and valproate alone (HR 0.740, 95 % CI 0.577-0.949), respectively, compared to that without lithium, valproate, or atypical antipsychotics. In the within-individual analysis, the HR for suicide incidents was 0.154 during treatment with lithium and atypical antipsychotics (95 % CI 0.055-0.428). When lithium, valproate, and atypical antipsychotics were combined, the HR was 0.235 (95 % CI 0.056-0.980). The HRs were 0.251 (95 % CI 0.090-0.698) for valproate alone and 0.302 (95 % CI 0.152-0.599) for valproate in combination with atypical antipsychotics.

CONCLUSIONS:

Suicide risk decreased during treatment with lithium or valproate alone. In patients with bipolar disorder who are at a high risk of suicide, atypical antipsychotics were associated with a reduced risk of suicide when combined with lithium or valproate.

01 Jan 2026·JOURNAL OF ETHNOPHARMACOLOGY

Neuropharmacological potentials (antipsychotic-, anxiolytic-, and antidepressant-like activities) of methanol leaf extract of Andrographis paniculata Nees in vivo: Possible mechanisms, antioxidant activity, and in silico supportive evidence

Article

Author: Terhemen, Memshima M ; Akawa, Oluwole ; Okpakpor, Elohor ; Bolanle, Israel O ; Ozolua, Raymond I

ETHNOPHARMACOLOGY RELEVANCE:

In Asia and parts of Africa, extracts from Andrographis paniculata Nees (Acanthaceae) are used as traditional remedies for a number of ailments such as tuberculosis, sinusitis, syphilis, leprosy, diarrhea, and malaria. There has been extensive research detailing the various pharmacological actions of Andrographis paniculata Nees (Acanthaceae). However, there is a paucity of scientific information on its neuropharmacological potential despite its traditional use to manage depression and anxiety in West Africa.

AIM OF STUDY:

This study aims to evaluate the neuropharmacological activities of Andrographis paniculata Nees (Acanthaceae) in mice.

METHODS:

Acute oral toxicity was evaluated on the methanol extract of Andrographis paniculata (MEAP) before screening it for neuropsychopharmacological properties including antipsychotic-like, anxiolytic-like, antidepressant-like, sedative-hypnotic, anticonvulsant, and motor coordination after administering it for 10 consecutive days using oral doses of 100, 200, 400 mg/kg. The principal constituent andrographolide was evaluated for antipsychotic-like property over a range of doses (2-32 mg/kg). The brains of MEAP-treated mice were assayed for antioxidant enzymes and lipid peroxidation. Molecular docking was used to evaluate the degree of binding of andrographolide to 5-HT_2A and D₂ receptors.

RESULTS:

MEAP is relatively safe with oral LD₅₀ > 5000 mg/kg. It significantly dose- and time-dependently attenuated amphetamine- and ketamine-induced psychosis-like behavior. The effect of andrographolide on amphetamine-induced psychosis-like behavior was significant only at 8 mg/kg dose. MEAP showed anxiolytic-like and antidepressant-like properties but did not enhance phenobarbitone-induced sleep. It did not protect the mice against chemically induced convulsions and did not affect the motor-coordinating ability of mice. MEAP significantly increased the brain levels of superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase, and reduced the levels of malondialdehyde. Andrographolide bound to D₂ and 5-HT_2A receptors but less than risperidone and aripiprazole at D₂ and 5-HT_2A, respectively.

CONCLUSION:

The methanol extract of Andrographis paniculata possesses antipsychotic-like property possibly mediated by one or more of its constituents rather than solely by andrographolide. It also possesses anxiolytic- and antidepressant-like actions. The brain antioxidant property of the extract complements its neuropsychopharmacological actions.

156

News (Medical) associated with Risperidone

19 Nov 2025

·www.fiercepharma.com

Teva calls on startups to Rise to the occasion with open innovation platform for 7 biopharma challenges

Teva expects to collect at least 100 applications from startups and hopes to choose pilot companies in March, a spokesperson told Fierce. Teva Pharmaceutical Industries is launching its first global innovation platform, challenging startups to submit novel strategies to tackle seven pervasive industry hurdles that run the gamut from manufacturing to R&D.The aim of the program, dubbed Teva Rise, is to introduce and accelerate novel solutions that can improve patients' lives and improve business efficiency, according to a Nov. 19 release. The initiative falls under the company’s ongoing “Pivot to Growth” strategy, an approach designed to foster innovation and help Teva become a leading biopharma company.Teva expects to collect at least 100 applications from startups and hopes to choose pilot companies in March, a spokesperson told Fierce. The number of companies selected will depend on the strength of the submissions, the spokesperson said.Companies chosen for the program will be able to showcase their technologies in real-world settings and “scale their impact across Teva’s global ecosystem," according to the release.Teva plans to commit “tens of millions” of dollars to the potential solutions generated through Rise, the company added. Meanwhile, “[t]he value proposition for startups goes beyond that, because, if selected, Rise also covers mentorship and funding,” Teva’s spokesperson told Fierce. Teva throws down the gauntlet The first of seven challenges for which Teva is seeking novel solutions revolves around human-predictive platforms for testing preclinical biologics. Specifically, the pharma is asking startups to submit scalable, validated tech alternatives to animal models, such as organ-on-a-chip or advanced cell culture sciences. The second area Teva is looking to tackle relates to clinical trial design. Teva wants to attract companies with artificial-intelligence-fueled protocol designs for study simulations that incorporate predictive analytics. The drugmaker is hoping the trial simulations can be used to ultimately improve protocol parameters and boost patient recruitment and retention.Apart from the more development-minded challenges laid out in the Rise program, Teva is also pressing startups to tackle hurdles related to commercialization, patient experience, manufacturing and supply chain stability. Rise challenge No. 3, for instance, looks to overhaul patient experiences with long-acting injectables—a topic close to Teva’s heart as the drugmaker strives to make a long-acting formulation of the atypical antipsychotic olanzapine a key part of its commercial schizophrenia repertoire. The company is specifically urging startups to explore digital health tools, smart devices or “behavioral science solutions” that monitor, support and improve patient perception of long-acting injectable drugs. Hitting on that goal has the potential to improve treatment outcomes for patients on these meds and to reduce healthcare costs overall, Teva argued. Nonadherence is a major issue in the use of long-acting injectable drugs, and especially so in the treatment of schizophrenia, where Teva hopes to make its mark with long-acting olanzapine and an extended-release version of risperidone, dubbed Uzedy, that snagged FDA clearance in 2023. Many of the other commercial-stage challenges laid out under Rise emphasize the potential of AI to reshape the way the industry tackles medicine supply, production and risk as well as what goes into the tough decisions drugmakers must make if inventory is strained. Challenge No. 4 tasks startups and tech outfits with rolling out advanced analytics platforms and AI-driven decision support tools to ensure drugmakers get the most out of global pharmaceutical tender processes, wherein governments, hospitals or other organizations take bids from multiple manufacturers for the supply of a medicine. Teva is further asking Rise participants to direct AI and machine learning tools toward asset reliability and maintenance, product quality and risk prediction, plus resource allocation.In essence, Teva is aiming to sponsor potential high-tech solutions that improve the reliability and efficiency of drug manufacturing, garner better insights into process risks and quality, and help improve decision-making to curb lost sales and minimize manual workloads during supply chain disruptions or shortages."Pharmaceutical manufacturers are operating under intense pressure to maintain efficiency, quality, and supply reliability amid increasing complexity," a representative for Teva explained in an emailed statement. "Today’s biggest challenges include global supply chain volatility, regulatory and quality expectations with greater focus on product traceability and process control," the representative continued. "These industry-wide realities are at the core of Teva’s commitment to implement smart manufacturing and transformation—building more resilient, data-driven, and responsive operations across its global footprint.”In many ways, the Rise platform reflects a broader change in Teva’s ethos over the past few years, driven in large part by the “Pivot to Growth” strategy rolled out by CEO Richard Francis early into his tenure at the company. While Teva for many years had been defined by its generic drug offerings, the company under Francis’ stewardship has leaned hard into its role as a generic and innovative medicines hybrid. Along with that reinvigorated emphasis on innovative medicines and novel formulations of older drugs, Teva has adopted more of a biotech mindset, Eric Hughes, M.D., Ph.D., the company’s executive vice president of global R&D and chief medical officer, explained in an interview with Fierce Pharma last fall. Working to improve facets of the drug game such as clinical trial design has been essential on Teva's mission to move multiple promising assets from its pipeline into the commercial realm, Hughes said at the time. So far, Francis’ strategy has paid off handsomely, with Teva earlier this month reporting its 11th consecutive quarter of sales growth after a protracted downturn for the company in the earlier part of the decade. “Our differentiated innovative portfolio is now a defining strength for Teva as we transform into a leading innovative biopharma, while our world-class generics business continues to provide a resilient foundation,” Francis said of the performance in a Nov. 5 earnings release.

Drug ApprovalExecutive Change

17 Nov 2025

·pharma.economictimes.indiatimes.com

Lupin launches generic injection in US with 180-day exclusivity

Mumbai: Drug maker Lupin on Friday said it has launched a generic medication to treat schizophrenia in the US with 180 days of exclusivity. The company has launched Risperidone for extended-release injectable suspension , 25 mg per vial, 37.5 mg per vial, and 50 mg per vial, single-dose vials, with 180-day CGT exclusivity in the US, the Mumbai-based drug maker said in a statement. This follows the recent approval received from the US Food and Drug Administration (USFDA). This is the company's first product using proprietary technology from PrecisionSphere, the Long-acting Injectable (LAI) platform developed by its subsidiary Nanomi BV. Risperidone for extended-release injectable suspension is bioequivalent and therapeutically equivalent to the reference listed drug Risperdal Consta LAI. It is indicated for the treatment of schizophrenia in adults and as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar disorder in adults. As per IQVIA MAT September 2025 data, Risperidone for extended-release injectable suspension has estimated sales of USD 187 million combined for 25 mg, 37.5 mg and 50 mg in the US. "It highlights our commitment to expanding our portfolio of differentiated, complex products, marking a significant step forward in our pursuit of developing novel long-acting injectables across diverse therapeutic areas," Lupin President US Generics Spiro Gavaris stated. Shares of the drug maker were trading 0.37 per cent down at Rs 2,045.40 apiece on BSE.

Drug Approval

14 Nov 2025

·www.prnewswire.com

Lupin Launches Risperidone Long-Acting Injectable with 180-day CGT exclusivity in the U.S., the First Product from its Proprietary Long-Acting Injectable Platform PrecisionSphere™

MUMBAI, India and NAPLES, Fla., Nov. 14, 2025 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the launch of Risperidone for extended-release injectable suspension, 25 mg per vial, 37.5 mg per vial, and 50 mg per vial, Single-Dose Vials, with 180-day CGT exclusivity in the U.S. This follows the recent approval received from the United States Food and Drug Administration (U.S. FDA). This is Lupin's first product using proprietary technology from PrecisionSphere™, the long-acting injectable (LAI) platform developed by Lupin's subsidiary Nanomi B.V.'s (Nanomi). Nanomi's LAI platform has demonstrated efficacy and safety in drug delivery. Its proprietary PrecisionSphere™ technology creates uniform microspheres that deliver extended-release profiles from weeks to months, superior injectability through smaller needles, and consistent drug concentrations. Lupin is expanding the reach of its PrecisionSphere™ technology by fostering collaborations with companies looking to extend their product lifecycles. "The launch of Risperidone marks a significant milestone, demonstrating Lupin's expertise in delivering complex injectables to market, validating the capabilities of the PrecisionSphere LAI technology platform," said Spiro Gavaris, President, U.S. Generics at Lupin. "It highlights our commitment to expanding our portfolio of differentiated, complex products, marking a significant step forward in our pursuit of developing novel long-acting injectables across diverse therapeutic areas." "PrecisionSphere's proven capabilities, combined with our track record of successful partnerships, uniquely position us to expand global access to advanced long-acting injectable treatments," said Dr. Fabrice Egros, President – Corporate Development, Lupin. "By leveraging our in-house expertise and alliance management, we are ready to expand patient access to advanced LAI treatments through our growing internal pipeline but also by forming new global strategic collaborations with companies that could benefit from longer-acting formulations for their products." About the product Risperidone for extended-release injectable suspension is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Risperdal Consta® Long-Acting Injection, and is indicated for the treatment of schizophrenia in adults and as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adults. Risperidone for extended-release injectable suspension (RLD Risperdal Consta®) has estimated sales of USD 187 million combined for 25 mg, 37.5 mg and 50 mg in the U.S. (IQVIA MAT September 2025). About Lupin Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 24,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions. To know more, visit or follow us on LinkedIn To know more about Nanomi, visit or follow on LinkedIn Logo: SOURCE Lupin Limited 21% more press release views with Request a Demo

Drug Approval

100 Deals associated with Risperidone

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00426	Risperidone	N05AX08	DB00734

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Autistic Disorder	United States	Janssen Pharmaceuticals, Inc.	06 Oct 2006
Irritable Mood	United States	Janssen Pharmaceuticals, Inc.	06 Oct 2006
Bipolar I disorder	United States	Janssen Pharmaceuticals, Inc.	04 Dec 2003
Aggression	South Korea	Myung in Pharm Co., Ltd.	02 Aug 2003
Alzheimer Disease	South Korea	Myung in Pharm Co., Ltd.	02 Aug 2003
Mania	South Korea	Myung in Pharm Co., Ltd.	02 Aug 2003
Self-Injurious Behavior	South Korea	Myung in Pharm Co., Ltd.	02 Aug 2003
Bipolar Disorder	United States	Janssen Pharmaceuticals, Inc.	03 Mar 2002
Schizophrenia	United States	Janssen Pharmaceuticals, Inc.	29 Dec 1993

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute schizophrenia	Phase 3	United States	Indivior, Inc.	01 Apr 2014
Suicidal Ideation	Phase 3	United States	Janssen Pharmaceuticals, Inc.	01 Jun 2004
Stress Disorders, Post-Traumatic	Phase 3	United States	Janssen Pharmaceuticals, Inc.	01 Apr 2004
Generalized anxiety disorder	Phase 3	United States	Janssen Pharmaceuticals, Inc.	01 Feb 2004
Panic	Phase 3	United States	Janssen Pharmaceuticals, Inc.	01 Feb 2004
Bipolar II disorder	Phase 3	-	Janssen, Inc.	01 Jan 2004
Child Behavior Disorders	Phase 3	-	Janssen-Cilag Ltd.	01 Sep 2003
Learning Disabilities	Phase 3	-	Janssen-Cilag Ltd.	01 Sep 2003
Depressive Disorder, Treatment-Resistant	Phase 3	-	Janssen LP	01 Oct 2002
Depressive Disorder, Treatment-Resistant	Phase 3	-	Johnson & Johnson Pharmaceutical Research & Development LLC	01 Oct 2002

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00539071 (CTgov)	Phase 4	Schizoaffective disorder \| Schizophrenia	160	long-acting injectable risperidone (Conventional Dose)	hasxnicndw(srbhvqqckh) = bkmbzxezyk siaafqcgqw (tqzehqgefw, 1.2) View more	-	06 Aug 2025
				long-acting injectable risperidone (High Dose Group)	hasxnicndw(srbhvqqckh) = scyvkldobw siaafqcgqw (tqzehqgefw, 1.3) View more
NEWS Manual	Not Applicable	Schizophrenia	-	UZEDY	acylfgwyuv(rlbxvvhmfu) = zlaoqpsidb szgswbydzp (nflirlhqra ) View more	Positive	31 May 2025
				Second Generation Oral Antipsychotics (SGOAs)	acylfgwyuv(rlbxvvhmfu) = gcjbwsgzlw szgswbydzp (nflirlhqra ) View more
P11-6.001 (AAN2025)	Not Applicable	Tourette Syndrome First line	1,684	D2 receptor antagonists (D2RAs)	llugxelfnn(howtdfqwdg) = kbkfqotszs covmfrutgc (ojeyyduknp )	Negative	07 Apr 2025
NCT04201834 (CTgov)	Phase 2	Huntington Disease	6	risperidone+BioStamp nPoint device	syqkifzfyj(czvvhlchag) = gupnluloai unjgvatizd (mlmfpenryi, dszpmvribh - xukdttehdr) View more	-	21 Mar 2025
NCT04418466 (DLP-114, CTgov)	Phase 1/2	Schizophrenia	34	risperidone (DLP-114 Alpha-4 (6-months))	lpxhenddje = bpsfwjfwdz debfzimaes (cvevdgluir, lgxeaxajey - dqxbpxpqnu) View more	-	27 Dec 2024
				risperidone (DLP-114 Alpha-7 (12-months))	lpxhenddje = lhtvxuxuka debfzimaes (cvevdgluir, eoyavjllez - waanzslyzv) View more
MDS2024	Not Applicable	Diabetes Mellitus	36	Risperidone	vrjdrqgxjq(zqjtqyzkgy) = uqtccflqgg vanfynkvan (nklhzevfuy, 6.45 - 15.8) View more	Positive	27 Sep 2024
NCT03323437 (CTgov)	Phase 4	Schizophrenia	26	Risperidone (Patient)	annjgayrky(gjdiivngjx) = aeedvowiyx tpeijnsomm (gpxftmlqlt, rphyfeftny - mjjywjtifj) View more	-	06 May 2024
				risperidone (Control)	annjgayrky(gjdiivngjx) = wybfrnpapy tpeijnsomm (gpxftmlqlt, hkmbbbgyet - cxwsbnnqxu) View more
NCT03160521 (FDA_CDER) Manual	Phase 3	Schizophrenia	390	RISVAN 75 mg	rxqbrykqel(crtijkbvpo) = fnmohxytoo vymjvbtvpd (rrndsxuepu, 1.51)	Positive	29 Mar 2024
				RISVAN 100 mg	rxqbrykqel(crtijkbvpo) = hgurhqagvh vymjvbtvpd (rrndsxuepu, 1.54)
NCT04418466 (PRNewswire) Manual	Phase 1/2	Schizophrenia	28	DLP-114	eszsmhyrer(hseasywxui) = No serious adverse events (AEs) attributed to DLP-114 were reported, and DLP-114 was well tolerated for up to 12 months, including the initial placement and follow-up removal procedures ttqtqcaqyu (louerrgfsy ) View more	Positive	16 Nov 2023
NCT03503318 (RISE, Literature) Manual	Phase 3	Schizophrenia	544	TV-46000 once monthlyTV-46000 once monthly	gdftcnrznx(gtbqjbiapq) = significantly prolonged by 5·0 times with TV-46000 once monthly (hazard ratio, 0·200 [95% CI 0·109–0·367]; p<0·0001) and by 2·7 times with TV-46000 once every 2 months (0·375 [0·227–0·618]; p<0·0001) versus placebo. xonqvrwwcu (ywazvbsmed ) View more	Positive	01 Nov 2023
				TV-46000TV-46000 once every 2 months